Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

類似資料

• Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer
  著者:: Li, Tianhong, 等
  出版事項: (2016)
• Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
  著者:: Ho, Cheryl, 等
  出版事項: (2013)
• Pharmacodynamic Separation of Gemcitabine and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer: Therapeutic and Biomarker Results
  著者:: Semrad, Thomas, 等
  出版事項: (2014)
• Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study
  著者:: Ho, Cheryl, 等
  出版事項: (2010)
• Phase II Study of the AKT inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer who Previously Progressed on Erlotinib
  著者:: Lara, Primo N., 等
  出版事項: (2015)